Peptide

MOTS-c

Also known as

Mitochondrial ORF of the Twelve S c · Mitochondrial open reading frame of the 12S rRNA-c · MOTS c · MOTSc · MOTS-C · mitochondrial-derived peptide MOTS-c · MRWQEMGYIFYPRKLR · MT-RNR1-encoded peptide

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	A 16-amino-acid mitochondrial signal discussed as an experimental injectable for endurance, energy and metabolic health. AMPK is the energy-sensing pathway invoked in its story.
Forms differ	SubQ reports lead; IM accounts are separate. Oral and sublingual marketing does not establish absorption or equivalence to injected MOTS-c. CB4211 is a different molecule.

Notes

MOTS-c is a small mitochondrial peptide discussed as an experimental injectable for endurance, energy and metabolic health. Some users describe easier workouts; others notice nothing, feel exhausted or develop painful injection reactions. The community experience is much broader than the “exercise in a vial” claim.

A small metabolic signal. Mitochondria help cells turn food into usable energy. MOTS-c is a 16-amino-acid signal linked to that system; AMPK is the energy-sensing pathway people invoke when discussing it. What is the MOTS-c peptide? (Official context · Accessed 2026-09-30) · Reynolds et al. — exercise-induced MOTS-c (2021) (Official context · Accessed 2026-09-30)

Injectable discussion leads. Subcutaneous means under the skin. IM means into muscle and appears in separate experiments. Oral/sublingual products are marketed, but the preserved discussion doubts their absorption; those forms are not equivalent to injected reports.

CB4211 is a different molecule. The sponsor’s analog trial used 25 mg SC daily for four weeks. That trial cannot supply native-MOTS-c amounts or benefits; its site-deposition problems are also formulation-specific. CohBar August 10 2021 investor presentation (Official context · Accessed 2026-09-30)

Source context — What is the MOTS-c peptide?: Official sport guidance; reported side effects are online reports, not incidence data. Legal/compounding statements not used to infer every current jurisdictional rule.

Source context — Reynolds et al. — exercise-induced MOTS-c (2021): Endogenous human exercise response; injected performance findings in mice. Not a human injected-dose PK, efficacy, longevity or safety study.

Source context — CohBar August 10 2021 investor presentation: Sponsor-authored commercial/investor material for a different molecule. Small exploratory analog trial; not native-MOTS-c dose or effectiveness evidence.

What people notice

Workout endurance	Some describe easier running, lifting or BJJ without greater energy at rest. One runner said the interval-running gain disappeared after stopping.
No result or fatigue	One user noticed no difference at 5 mg three times weekly for over four weeks. Others describe exhaustion or initial energy followed by feeling sick and sore.
Weight-loss hopes	A retatrutide user associated it with renewed weight loss after a plateau, alongside diet, exercise and the other drug. That does not isolate MOTS-c's effect.

Notes

More endurance during activity. Accounts describe easier running, lifting or BJJ rounds, sometimes without feeling more energized at rest. One runner reported faster intervals, then said the gain disappeared after stopping. MOTS-C CYCLE (Community discussion · Accessed 2026-09-30) · Does anyone try MOTS-c? (Personal report · Accessed 2026-09-30)

No change is also a real report. A contributor described 5 mg three times weekly for over four weeks with no noticeable difference. An immediate “superhuman” response is not a reliable expectation. How long to feel mots-c (Community discussion · Accessed 2026-09-30)

First dose and later doses can differ. The 5 mg twice-weekly author felt clear and energized initially, then sick and sore on later injections. A strong first experience did not predict continued benefit. Mots-C experience (Community discussion · Accessed 2026-09-30)

Painful sites, fatigue and stomach symptoms. Reports include redness, itching, hard swollen areas lasting days, nausea and marked exhaustion. Other reports include flushing, headaches 2–6 hours after injection and flat mood around weeks 3–4; incidence and causation are unknown.

Fat loss and metabolic flexibility are sought. One Reta user associated MOTS-c with renewed weight loss after a plateau. Diet, exercise and another metabolic drug changed the picture; this cannot isolate a peptide fat-loss effect. MOTS-c — what’s your experience with it? (Community discussion · Accessed 2026-09-30)

Source context — MOTS-C CYCLE: Self-reports and proposed plans are distinct. Route not specified. Community promotes its own guides; no tested sequencing or timing comparison.

Source context — Does anyone try MOTS-c?: Individual uncontrolled runner, amount unstated; native MOTS-c and CB4211 trial material conflated in thread. Sourcing links present but not reproduced.

Source context — How long to feel mots-c: No verified products, onset amount/route incompletely specified; promotional guide environment. Published date from search-visible dated thread, not relative timestamp conversion.

Source context — Mots-C experience: Anonymous, unverified injections and amounts; routes not explicit in every comment. Subreddit sponsor and affiliate links visible. Concurrent hormone/peptide use and training confound reports.

Source context — MOTS-c — what’s your experience with it?: Anonymous, multiple stacks, diet/training and medication changes; testimonial and physiological conjecture mixed. No exact amount in verymuchfull duration account.

Doses people talk about

SubQ weekly totals	Charts describe 5 mg once weekly, 2.5 mg twice weekly or 5 mg once/twice weekly: 5–10 mg per week, not per day.
Larger boluses	5 mg three times weekly totals 15 mg/week. Separate higher reports include 10 mg 2–3 times weekly and 20 mg three times weekly within a large stack; these are not escalation steps.
Smaller frequent amounts	Separate accounts describe 500 mcg five days/week, 1 mg daily or 2 mg five days/week. The per-injection amount and weekly total are different questions.
IM account	One author used 1–1.5 mg IM, reporting initial benefit then dizziness and no further endurance benefit. This does not establish an equivalent SubQ amount.

Notes

SC weekly totals: 5–10 mg. Circulated charts describe 5 mg once weekly, 2.5 mg twice weekly, or 5 mg once/twice weekly. These are distinct schedules totaling 5–10 mg/week, not daily amounts or validated standards.

Larger boluses: 5 mg three times weekly. That is 15 mg/week. Clinic/forum charts also contain 10 mg two/three times weekly; a fresh commenter reports 20 mg three times weekly inside a large stack. These higher amounts are separate reports, not an escalation ladder. Mots-C experience (Community discussion · Accessed 2026-09-30)

Smaller frequent injections: 0.5–2 mg. Examples include 500 mcg (0.5 mg) five days/week, 1 mg daily and 2 mg five days/week. Other charts list 1–1.5 mg weekdays. Frequent-use totals differ; less per injection does not necessarily mean less per week. Mots-C experience (Community discussion · Accessed 2026-09-30) · MOTS-C CYCLE (Community discussion · Accessed 2026-09-30)

IM: one account used 1–1.5 mg. Its author reported initial benefit followed by dizziness and no further endurance benefit. This minority route does not establish an equivalent SC dose. Mots C Effects/Sides (Personal report · Accessed 2026-09-30)

Source context — MOTS-C CYCLE: Self-reports and proposed plans are distinct. Route not specified. Community promotes its own guides; no tested sequencing or timing comparison.

Source context — Mots C Effects/Sides: Forum has supplier/coach promotion. Claimed verified product not independently verified. Author’s assumption that food excludes glucose problems is not a clinical finding.

Half-life, onset & duration

Felt onset	One incompletely specified account described restlessness and wanting activity after 30–90 minutes. A first-dose response did not always continue.
Felt duration	One account said a workout effect was gone about four hours after exercise, with amount unstated. Separate IM dizziness/flatness lasted 4–6 hours. Neither measures clearance.
Half-life	Injected human half-life is not established here. Two-hour claims are unmeasured; the human four-hour exercise result concerns natural MOTS-c returning to baseline without an injection.

Notes

One account: 30–90 minutes after injection. That contributor described restlessness and wanting physical work. Others report no change after days or weeks; onset amount and route are incompletely specified in this account. How long to feel mots-c (Community discussion · Accessed 2026-09-30)

One workout account: gone about 4 hours after exercise. The author used it fed before training, but did not state an amount. This is a felt window measured from the workout, not a four-hour elimination half-life. MOTS-c — what’s your experience with it? (Community discussion · Accessed 2026-09-30)

An adverse IM experience lasted 4–6 hours. Dizziness and flatness after exercise followed 1–1.5 mg injections. Benefit duration and symptom duration are different questions; neither gives a dependable clearance interval. Mots C Effects/Sides (Personal report · Accessed 2026-09-30)

Two hours is a circulating claim. A September 2026 timing commenter states it without a measurement. A different discussion calls couple-hour kinetics rodent-derived and challenges human extrapolation. Neither establishes injected human half-life. Mots C Timing (Community discussion · Accessed 2026-09-30) · MOTS-C Dosing and Results (Community discussion · Accessed 2026-09-30)

The four-hour exercise result is endogenous. In ten young men, plasma MOTS-c returned to baseline four hours after exercise, while muscle levels remained raised. No MOTS-c injection was given; this does not measure injected human half-life. Reynolds et al. — exercise-induced MOTS-c (2021) (Official context · Accessed 2026-09-30)

Source context — Mots C Timing: No cited measurement supports two-hour number. Pre-workout mechanisms are commenters' theories; evening experiences contradict a blanket insomnia prediction.

Source context — MOTS-C Dosing and Results: Rodent claim is a commenter’s secondhand attribution, not independently verified animal PK. Self-timed swimming is uncontrolled.

Cycles people discuss

Weekly-use blocks	Charts describe 4–8 or 8–12 weeks on, with competing 2–4 or 4–8-week breaks. One account used four weeks twice weekly, then four weeks three times weekly.
Twenty-day pulse	A separate chart describes four 5 mg SubQ injections every five days, about 20 mg total, then 3–6 months off. It is distinct from continuous weekly use.
Other calendars	Eight on/four off with load/maintenance amounts is another chart. Conflicting break lengths do not establish tolerance prevention or long-term safety.

Notes

Four to eight weeks; longer 8–12-week blocks. Other charts include 2–4 or 4–8 weeks off. One fresh cyclist described four weeks at 5 mg twice weekly, then four at 5 mg three times weekly. These are reports, not a tested cycle. MOTS-c — what’s your experience with it? (Community discussion · Accessed 2026-09-30)

Twenty-day pulse: four 5 mg SC injections. The circulated chart describes every five days, about 20 mg total, then 3–6 months off. This is distinct from continuous weekly use; it is not a validated course.

Eight on/four off is another chart. It pairs an approximately 10 mg/week load with 5 mg/week maintenance. A BJJ contributor planned to stop at week six. Break lengths conflict and do not establish tolerance prevention or long-term safety. MOTS-C CYCLE (Community discussion · Accessed 2026-09-30)

Source context — MOTS-C CYCLE: Self-reports and proposed plans are distinct. Route not specified. Community promotes its own guides; no tested sequencing or timing comparison.

Stacks

SS-31 sequence debate	Some charts place SS-31 first for 2–4+ weeks, then MOTS-c; others reverse or overlap them. No preferred order is established.
Other metabolic partners	NAD+, NMN/NR, humanin, GLP-1 drugs, SLU-PP-332, hormones and other peptides appear in mixed logs. Metformin/berberine overlap is debated without a checked interaction map.
Folate add-ons	Folate, methylated vitamins and TMG are proposed for fatigue. Cell mechanisms do not establish a human deficiency or show that these add-ons fix the reactions.

Notes

SS-31 first, MOTS-c first, or overlap? Stack charts describe 2–4+ weeks of SS-31 first, often 5–10 mg/day SC, followed by MOTS-c; others reverse or overlap them. Fresh users still disagree. NAD+, NMN/NR and humanin also enter stacks, preventing clean attribution.

Stacks can improve or complicate the story. GLP-1 drugs, SLU-PP-332, hormones and other peptides appear beside positive and adverse accounts. Commenters also debate overlapping AMPK stories with metformin/berberine; no checked interaction map follows. Fatigue on Mots-C (Community discussion · Accessed 2026-09-30)

Folate explanations are not proven fixes. Commenters blame fatigue on folate depletion and recommend methylated vitamins. The cited cell mechanism does not demonstrate a human deficiency or establish that folate, TMG, NAD+ or SS-31 resolves these reactions. Mots-C experience (Community discussion · Accessed 2026-09-30) · FDA MOTS-c briefing for July 2026 PCAC (Official context · Accessed 2026-09-30)

Source context — Fatigue on Mots-C: Baseline symptom predates MOTS-c; multiple agents and coffee make causation unclear. Cannot label this a newly induced crash or a transient adjustment.

Source context — FDA MOTS-c briefing for July 2026 PCAC: FDA reviewer briefing is not a final rule or committee vote record. Cell mechanism does not establish human folate depletion or a supplement requirement.

Watch for

Sites and fatigue	Redness, itching, hard swollen areas lasting days, nausea, headaches and marked exhaustion appear in accounts. Improved endurance does not rule out poor tolerability.
Hunger, heart and sleep	Shaky or crash-like feelings do not prove hypoglycemia. Online reports also include palpitations, sleep disruption and immune reactions; labels and testing claims do not establish safety.
Human evidence and sport	Human benefit and long-term safety remain unestablished. The saved sport guidance identifies MOTS-c as prohibited at all times; community timing claims give no test-clearance interval.

Notes

Hunger or shakiness is not a glucose diagnosis. Users describe increased hunger or “crashes,” including with GLP-1 drugs and reduced eating. In one week-four fatigue thread, the midday slump already existed for years. These accounts do not prove hypoglycemia. Fatigue on Mots-C (Community discussion · Accessed 2026-09-30)

Palpitations, sleep disruption and immune reactions are reported. USADA includes these and fever among online adverse reports. Research-only labels and testing claims do not establish safety, purity or suitability in pregnancy or medical conditions. What is the MOTS-c peptide? (Official context · Accessed 2026-09-30)

Human benefit and long-term safety remain unestablished. FDA’s July 2026 briefing flags missing human evidence and immune-safety information. A compounding discussion or committee recommendation is not drug approval. FDA MOTS-c briefing for July 2026 PCAC (Official context · Accessed 2026-09-30)

Sport prohibition is separate from pharmacy debate. USADA identifies MOTS-c as prohibited at all times under WADA’s AMPK-activator category. Community timing estimates provide no clearance interval for athletes. What is the MOTS-c peptide? (Official context · Accessed 2026-09-30)

Source context — Fatigue on Mots-C: Baseline symptom predates MOTS-c; multiple agents and coffee make causation unclear. Cannot label this a newly induced crash or a transient adjustment.

Full notes

What MOTS-c is

A small metabolic signal. Mitochondria help cells turn food into usable energy. MOTS-c is a 16-amino-acid signal linked to that system; AMPK is the energy-sensing pathway people invoke when discussing it. Official context Official context
Injectable discussion leads. Subcutaneous means under the skin. IM means into muscle and appears in separate experiments. Oral/sublingual products are marketed, but the preserved discussion doubts their absorption; those forms are not equivalent to injected reports. Community

Benefits people look for

More endurance during activity. Accounts describe easier running, lifting or BJJ rounds, sometimes without feeling more energized at rest. One runner reported faster intervals, then said the gain disappeared after stopping. Reddit · r/BodyHackGuide Personal report
Fat loss and metabolic flexibility are sought. One Reta user associated MOTS-c with renewed weight loss after a plateau. Diet, exercise and another metabolic drug changed the picture; this cannot isolate a peptide fat-loss effect. Reddit · r/Biohacking
No change is also a real report. A contributor described 5 mg three times weekly for over four weeks with no noticeable difference. An immediate “superhuman” response is not a reliable expectation. Reddit · r/BodyHackGuide

Doses people discuss

SC weekly totals: 5–10 mg. Circulated charts describe 5 mg once weekly, 2.5 mg twice weekly, or 5 mg once/twice weekly. These are distinct schedules totaling 5–10 mg/week, not daily amounts or validated standards. Community
Larger boluses: 5 mg three times weekly. That is 15 mg/week. Clinic/forum charts also contain 10 mg two/three times weekly; a fresh commenter reports 20 mg three times weekly inside a large stack. These higher amounts are separate reports, not an escalation ladder. Community Reddit · r/PeptideGuide
Smaller frequent injections: 0.5–2 mg. Examples include 500 mcg (0.5 mg) five days/week, 1 mg daily and 2 mg five days/week. Other charts list 1–1.5 mg weekdays. Frequent-use totals differ; less per injection does not necessarily mean less per week. Reddit · r/PeptideGuide Reddit · r/BodyHackGuide Community
Commercial tables: 5, 7.5 or 10 mg per injection. Vendor ladders use these amounts and roughly four-week load/maintenance narratives. They are marketing-derived schedules, not proof of effectiveness or safe upper limits. Community
IM: one account used 1–1.5 mg. Its author reported initial benefit followed by dizziness and no further endurance benefit. This minority route does not establish an equivalent SC dose. Personal report

Half-life discussed in the community

Two hours is a circulating claim. A September 2026 timing commenter states it without a measurement. A different discussion calls couple-hour kinetics rodent-derived and challenges human extrapolation. Neither establishes injected human half-life. Reddit · r/Biohacking Reddit · r/Biohacking
Short blood presence does not settle the schedule. Community explanations invoke short clearance to justify weekly boluses or daily injections, while claiming signaling may last days/weeks. Those explanations are not measured human timing rules. Community

When people notice it

One account: 30–90 minutes after injection. That contributor described restlessness and wanting physical work. Others report no change after days or weeks; onset amount and route are incompletely specified in this account. Reddit · r/BodyHackGuide
First dose and later doses can differ. The 5 mg twice-weekly author felt clear and energized initially, then sick and sore on later injections. A strong first experience did not predict continued benefit. Reddit · r/PeptideGuide

How long the experience lasts

One workout account: gone about 4 hours after exercise. The author used it fed before training, but did not state an amount. This is a felt window measured from the workout, not a four-hour elimination half-life. Reddit · r/Biohacking
An adverse IM experience lasted 4–6 hours. Dizziness and flatness after exercise followed 1–1.5 mg injections. Benefit duration and symptom duration are different questions; neither gives a dependable clearance interval. Personal report
Lasting changes remain uncertain. The runner’s gain faded after stopping. Claims of days/weeks of downstream signaling and 4–8-week body-composition changes do not establish durable adaptation from one injection. Personal report Community

Courses and breaks people describe

Four to eight weeks; longer 8–12-week blocks. Other charts include 2–4 or 4–8 weeks off. One fresh cyclist described four weeks at 5 mg twice weekly, then four at 5 mg three times weekly. These are reports, not a tested cycle. Community Reddit · r/Biohacking
Twenty-day pulse: four 5 mg SC injections. The circulated chart describes every five days, about 20 mg total, then 3–6 months off. This is distinct from continuous weekly use; it is not a validated course. Community Community
Eight on/four off is another chart. It pairs an approximately 10 mg/week load with 5 mg/week maintenance. A BJJ contributor planned to stop at week six. Break lengths conflict and do not establish tolerance prevention or long-term safety. Community Reddit · r/BodyHackGuide

Watch for

Painful sites, fatigue and stomach symptoms. Reports include redness, itching, hard swollen areas lasting days, nausea and marked exhaustion. Other reports include flushing, headaches 2–6 hours after injection and flat mood around weeks 3–4; incidence and causation are unknown. Community
Hunger or shakiness is not a glucose diagnosis. Users describe increased hunger or “crashes,” including with GLP-1 drugs and reduced eating. In one week-four fatigue thread, the midday slump already existed for years. These accounts do not prove hypoglycemia. Reddit · r/Peptidesource Community
Palpitations, sleep disruption and immune reactions are reported. USADA includes these and fever among online adverse reports. Research-only labels and testing claims do not establish safety, purity or suitability in pregnancy or medical conditions. Official context Community
Human benefit and long-term safety remain unestablished. FDA’s July 2026 briefing flags missing human evidence and immune-safety information. A compounding discussion or committee recommendation is not drug approval. Official context

From community discussion

SS-31 first, MOTS-c first, or overlap? Stack charts describe 2–4+ weeks of SS-31 first, often 5–10 mg/day SC, followed by MOTS-c; others reverse or overlap them. Fresh users still disagree. NAD+, NMN/NR and humanin also enter stacks, preventing clean attribution. Community
Training timing and food are debated. One 5 mg twice-weekly account preferred two hours before exercise after morning yawning. Others use it fed; fasted morning charts also circulate. Evening users describe stamina with normal sleep. No timing or food winner is established. Reddit · r/BodyHackGuide Reddit · r/Biohacking Reddit · r/Biohacking Community
Folate explanations are not proven fixes. Commenters blame fatigue on folate depletion and recommend methylated vitamins. The cited cell mechanism does not demonstrate a human deficiency or establish that folate, TMG, NAD+ or SS-31 resolves these reactions. Reddit · r/PeptideGuide Official context
Stacks can improve or complicate the story. GLP-1 drugs, SLU-PP-332, hormones and other peptides appear beside positive and adverse accounts. Commenters also debate overlapping AMPK stories with metformin/berberine; no checked interaction map follows. Reddit · r/Peptidesource Community
ATX-304 comparisons concern a different product. Comparison talk contrasts oral 100–150 mg ATX-304 with injected MOTS-c weekly amounts. This comparison lore does not establish interchangeability or a head-to-head result. Community

Supporting research context

The four-hour exercise result is endogenous. In ten young men, plasma MOTS-c returned to baseline four hours after exercise, while muscle levels remained raised. No MOTS-c injection was given; this does not measure injected human half-life. Official context
CB4211 is a different molecule. The sponsor’s analog trial used 25 mg SC daily for four weeks. That trial cannot supply native-MOTS-c amounts or benefits; its site-deposition problems are also formulation-specific. Official context
Sport prohibition is separate from pharmacy debate. USADA identifies MOTS-c as prohibited at all times under WADA’s AMPK-activator category. Community timing estimates provide no clearance interval for athletes. Official context